Group 1 - The company is in a strong position, supported by a robust portfolio of commercial products addressing significant medical needs [2] - Growth expectations for 2025 are driven by strengths in oncology, animal health, and new product launches, which are anticipated to offset challenges from GARDASIL in China [3] - The company aims to sustain strong growth into 2026 and 2027, with a focus on execution and performance of existing and new products [3]

As filed with the Securities and Exchange Commission on February 14, 2024 Registration No. 333-[_] UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 _____________________ Onconetix, Inc. (Exact Name of Registrant as Specified in its Charter) _____________________ (State or other jurisdiction of incorporation or organization) Delaware 2834 83-2262816 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer ...

As filed with the Securities and Exchange Commission on February 14, 2024 Registration No. 333-[_] UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (State or other jurisdiction of incorporation or organization) (Exact Name of Registrant as Specified in its Charter) _____________________ Delaware 2834 83-2262816 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification No.) 201 E. Fifth Street, Suite 1900 Cincinnati, Ohio 45202 Telephone: (513) 620-4101 F ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 KAZIA THERAPEUTICS LIMITED (Exact name of Registrant as specified in its charter) As filed with the Securities and Exchange Commission on January 30, 2024 (State or other jurisdiction of incorporation or organization) Registration No. 333- Australia 2834 Not applicable (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identificatio ...

Table of Contents As filed with the U.S. Securities and Exchange Commission on December 14, 2023. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 3 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) 3841 (Primary Standard Industrial Delaware (State or other jurisdiction of incorporation or organization) Classification Code Number) 6272 W. 91st Ave. Westminster, Colorado ...

Table of Contents As filed with the U.S. Securities and Exchange Commission on September 1, 2023. Registration No. 333-274292 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) 3841 Delaware (State or other jurisdiction of incorporation or organization) Westminster, Colorado 80031 (888) 321-5212 (Address, including zip co ...